Skip to main content
Premium Trial:

Request an Annual Quote

On His Way Out

The CEO of Biogen Idec, James Mullen, will be leaving the company in June after "seven turbulent years," says Fierce Biotech. During his tenure, Mullen oversaw the approval and marketing of Tysabr, to treat multiple sclerosis, which was then linked to rare, deadly brain infections. He also faced criticisms from investor Carl Icahn, including on the company's record of product development record, adds the Wall Street Journal.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.